巴克莱公司降低了固体生物科学的价格目标,而其他公司则提高了评级。 Barclays lowered Solid Biosciences' price target while other firms upgraded their ratings.
巴克莱将Solid Biosciences的目标价从18.00美元下调至15.00美元，而Leerink Partners、Piper Sandler、SVB Leerink、HC Wainwright和JPMorgan Chase & Co等其他公司上调了对这家生命科学公司的评级和目标。 Barclays lowered Solid Biosciences' price target from $18.00 to $15.00, while other firms like Leerink Partners, Piper Sandler, SVB Leerink, HC Wainwright, and JPMorgan Chase & Co upgraded their ratings and targets for the life science company. 固体生物科学的重点是发展神经肌肉和心脏疾病的治疗方法,主要产品候选者SGT-003和SGT-501。 Solid Biosciences focuses on developing therapies for neuromuscular and cardiac diseases, with lead product candidates SGT-003 and SGT-501. 该公司的市场上限为3.4238亿美元,贝塔为1.84美元。 The company has a market cap of $342.38m and a beta of 1.84.